Ribeiro Alice M, Amaral André C, Felipe Maria Sueli S, Bocca Anamelia L
Institute of Biological Sciences, University of Brasilia, Brasilia, Brazil.
Tropical Pathology and Public Health Institute, Federal University of Goiás, Goiânia, Brazil.
Methods Mol Biol. 2017;1625:85-96. doi: 10.1007/978-1-4939-7104-6_7.
The conventional treatment for fungal diseases usually shows long periods of therapy and the high frequency of relapses and sequels. New strategies of the treatment are necessary. We have shown that the Mycobacterium leprae HSP65 gene can be successfully used as therapy against murine Paracoccidioidomycosis (PCM). Here, we described the methodology of DNAhsp65 immunotherapy in mice infected with the dimorphic fungus Paracoccidioides brasiliensis, one of PCM agent, evaluating cytokines levels, fungal burden, and lung injury. Our results provide a new prospective on the immunotherapy of mycosis.
真菌疾病的传统治疗通常显示出治疗周期长、复发和后遗症频率高的特点。因此需要新的治疗策略。我们已经表明，麻风分枝杆菌HSP65基因可以成功地用于治疗小鼠副球孢子菌病（PCM）。在此，我们描述了用DNAhsp65对感染双态真菌巴西副球孢子菌（PCM病原体之一）的小鼠进行免疫治疗的方法，评估细胞因子水平、真菌负荷和肺损伤。我们的结果为真菌病的免疫治疗提供了新的前景。
